Aerovance Names Mark L. Perry President and CEO

BERKELEY, Calif., Feb. 1st, 2007 – Aerovance, Inc. today announced the appointment of Mark L. Perry, currently the company’s executive chairman, as president and chief executive officer.
Perry, 51, has been a member of Aerovance’s board of directors since October 2004, and was named chairman in 2006. Perry will remain on the Aerovance board, although he will no longer be chairman. His appointment comes at a time that Aerovance is expanding its leadership team and advancing its asthma, eczema and cystic fibrosis drug candidates through Phase 2 clinical trials.

“Mark has been a leader on Aerovance’s board since the company’s inception and has played an integral role in its success to date” said Nick Galakatos, an Aerovance board member and managing director of Clarus Ventures, which led the company’s Series C financing in May 2006. “As a result, Aerovance’s board and management are thrilled by Mark’s decision to join Aerovance on a full-time basis. He will lead a highly experienced team of executives with deep expertise in developing and commercializing respiratory therapeutics.”

Perry is currently the senior business advisor at Gilead Sciences Inc. (GILD), where he advises senior management and the board of directors on corporate development, marketing, investor relations and strategic initiatives. From 1994 to 2004, Perry held a variety of executive positions at Gilead, including general counsel, chief financial officer and executive vice president of operations. His responsibilities as head of operations included management of the Gilead’s worldwide sales and marketing, legal, manufacturing and facilities functions.

From 1981 to 1994, Perry worked with the law firm of Cooley Godward LLP in San Francisco, serving as a partner of the firm from 1987 to 1994. His practice was focused on corporate and securities law, with an emphasis on representation of life science companies.
Perry is also a director of Nuvelo Inc. (NUVO) and Nvidia Corporation (NVDA). He received his J.D. from the University of California, Davis, and a bachelor’s degree from the University of California, Berkeley.

Aerovance, Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. The company’s lead products are AEROVANT™, an IL4/13 receptor antagonist for severe asthma and eczema that is currently in Phase 2 clinical studies, and AEROLYTIC™, a recombinant protein for the
treatment of cystic fibrosis that is currently in Phase 2 clinical studies. In addition to these investigational products, Aerovance has several preclinical programs in respiratory and inflammatory disease.

Media Contact:
Tracey Milani
Russo Partners, LLC
(619) 814-3511
tracey.milani@russopartnersllc.com

back to the top